Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy

被引:9
作者
Fantini, Massimo [1 ]
Arlen, Philip Martin [1 ]
Tsang, Kwong Yok [1 ]
机构
[1] Precis Biol Inc, Bethesda, MD 20814 USA
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
NK cells; ADCC; modulatory cytokines; adoptive NK cell therapy; monoclonal antibody; CAR-NK; LONG-TERM SAFETY; METASTATIC UROTHELIAL CARCINOMA; GAMMA-RIIIA POLYMORPHISMS; C-RECEPTOR POLYMORPHISMS; PHASE-I; COLORECTAL-CANCER; CORD BLOOD; MEDIATED CYTOTOXICITY; IMMUNE-SYSTEM; SOLUBLE MICA;
D O I
10.3389/fimmu.2023.1275904
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Natural killer (NK) cells are cellular components of the innate immune system that can recognize and suppress the proliferation of cancer cells. NK cells can eliminate cancer cells through direct lysis, by secreting perforin and granzymes, or through antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC involves the binding of the Fc gamma receptor IIIa (CD16), present on NK cells, to the constant region of an antibody already bound to cancer cells. Cancer cells use several mechanisms to evade antitumor activity of NK cells, including the accumulation of inhibitory cytokines, recruitment and expansion of immune suppressor cells such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), modulation of ligands for NK cells receptors. Several strategies have been developed to enhance the antitumor activity of NK cells with the goal of overcoming cancer cells resistance to NK cells. The three main strategies to engineer and boost NK cells cytotoxicity include boosting NK cells with modulatory cytokines, adoptive NK cell therapy, and the employment of engineered NK cells to enhance antibody-based immunotherapy. Although the first two strategies improved the efficacy of NK cell-based therapy, there are still some limitations, including immune-related adverse events, induction of immune-suppressive cells and further cancer resistance to NK cell killing. One strategy to overcome these issues is the combination of monoclonal antibodies (mAbs) that mediate ADCC and engineered NK cells with potentiated anti-cancer activity. The advantage of using mAbs with ADCC activity is that they can activate NK cells, but also favor the accumulation of immune effector cells to the tumor microenvironment (TME). Several clinical trials reported that combining engineered NK cells with mAbs with ADCC activity can result in a superior clinical response compared to mAbs alone. Next generation of clinical trials, employing engineered NK cells with mAbs with higher affinity for CD16 expressed on NK cells, will provide more effective and higher-quality treatments to cancer patients.
引用
收藏
页数:20
相关论文
共 50 条
[31]   The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy [J].
Yu, Yanlin .
CANCERS, 2023, 15 (08)
[32]   Current and Future States of Natural Killer Cell-Based Immunotherapy in Hepatocellular Carcinoma [J].
Nguyen, Tu ;
Chen, Po -Chun ;
Pham, Janet ;
Kaur, Kawaljit ;
Raman, Steven S. ;
Jewett, Anahid ;
Chiang, Jason .
CRITICAL REVIEWS IN IMMUNOLOGY, 2024, 44 (05)
[33]   Current progress in cancer immunotherapy based on natural killer cells [J].
Bagheri, Yasin ;
Barati, Alireza ;
Aghebati-Maleki, Ali ;
Aghebati-Maleki, Leili ;
Yousefi, Mehdi .
CELL BIOLOGY INTERNATIONAL, 2021, 45 (01) :2-17
[34]   NK cell-based tumor immunotherapy [J].
Zhang, Hao ;
Yang, Li ;
Wang, Tingting ;
Li, Zhen .
BIOACTIVE MATERIALS, 2024, 31 :63-86
[35]   NK Cell-Based Glioblastoma Immunotherapy [J].
Golan, Irene ;
Rodriguez de la Fuente, Laura ;
Costoya, Jose A. .
CANCERS, 2018, 10 (12)
[36]   Neutrophils in antibody-based immunotherapy of cancer [J].
van Egmond, Marjolein .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (01) :83-94
[37]   Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells [J].
Ferreira-Teixeira, Margarida ;
Paiva-Oliveira, Daniela ;
Parada, Belmiro ;
Alves, Vera ;
Sousa, Vitor ;
Chijioke, Obinna ;
Munz, Christian ;
Reis, Flavio ;
Rodrigues-Santos, Paulo ;
Gomes, Celia .
BMC MEDICINE, 2016, 14
[38]   Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy [J].
Zhou, Q. ;
Gil-Krzewska, A. ;
Peruzzi, G. ;
Borrego, F. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 173 (01) :131-139
[39]   New views on natural killer cell-based immunotherapy for melanoma treatment [J].
Burke, Shannon ;
Lakshmikanth, Tadepally ;
Colucci, Francesco ;
Carbone, Ennio .
TRENDS IN IMMUNOLOGY, 2010, 31 (09) :339-345
[40]   Natural killer cell-based therapies in neuroblastoma [J].
Ghasempour, Abtin ;
Mohseni, Rashin ;
Sharif, Pouya Mahdavi ;
Hamidieh, Amir Ali .
CELLULAR IMMUNOLOGY, 2025, 407